Click here for the EyeWorld Show Daily Wrap-Up
View Latest Issue
Clinical Study Update: Surgical Therapeutics
Aqueous Penetration and Biological Activity of Moxifloxacin 0.5% and Gatifloxacin 0.3% Ophthalmic Solutions in Cataract Surgery Patients
Moxifloxacin shown to have greater potency and better penetration
Stephen S. Lane, M.D
A Double-Masked, Randomized, Single-Dose, Pharmacokinetic Study of NEVANAC® Suspension, ACULAR* LS, or XIBROM* in Human Aqueous Humor
NEVANAC® suspension shows greater ocular bioavailability than other NSAIDs
Michael B. Raizman, M.D.
Human Corneal Concentrations of Moxifloxacin and Gatifloxacin in a Penetrating Keratoplasty Model
VIGAMOX® solution shown to have greater human corneal concentration than ZYMAR*
Terry Kim, M.D.
A Double-Masked Study of Nepafenac 0.1% and Ketorolac 0.4% for Pain and Epithelial Healing Following PRK
Epithelial healing shown to be equivalent among NSAIDs
Daniel S. Durrie, M.D.
Evaluation of the Safety of Prophylactic Intracameral VIGAMOX® Solution in Cataract Surgery Patients
Intracameral VIGAMOX® solution shown to be safe after cataract surgery
Francis Mah, M.D.
Placebo-Controlled Trial of NEVANAC® Suspension and ACULAR* for Treatment of Ocular Pain and Inflammation Following Cataract Surgery
NEVANAC® suspension effective for post-op cataract surgery inflammation and pain
Edward J. Holland, M.D.
Advertise with Us
Copyright © 1997-2013 EyeWorld News Service
This site is optimized for 1024 X 768 Resolution
for a PDA optimized experience